Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lyvepodimab
- Development stage
- Preclinical
- Lead developer
- Kekkan Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lyvepodimab (KB001) is a bispecific monoclonal antibody developed by Kekkan Biologics, currently in preclinical development for the treatment of triple-negative breast cancer (TNBC). The molecule is designed to simultaneously target Programmed Cell Death Protein 1 (PD-1) and Lymphatic Vessel-derived Regulatory Factor (LVRF). By inhibiting PD-1, lyvepodimab acts as a checkpoint inhibitor to restore T-cell mediated anti-tumor immunity. The targeting of LVRF, a factor associated with the tumor vasculature and lymphatic environment, is intended to modulate the tumor microenvironment to enhance therapeutic efficacy. The program has demonstrated in vitro and in vivo proof-of-concept and has undergone humanization.
- Other names
- lyvepodimabKB001KB-001KB 001
02
Targets
LVRF (Lymphatic and vascular resistant factor)PDCD1 (Programmed cell death protein 1 receptor)ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on lyvepodimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lyvepodimab.